Monoclonal antibody against monkeypox virus m1r protein and use thereof
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- INST OF MICROBIOLOGY CHINESE ACAD OF SCI
- Filing Date
- 2025-03-17
- Publication Date
- 2026-05-26
AI Technical Summary
The lack of high-affinity and in vitro neutralizing monkeypox virus antibodies in existing technologies makes it difficult to prevent and control monkeypox virus infection. Furthermore, monkeypox virus mutates rapidly during human-to-human transmission, threatening global public health security.
Monoclonal antibodies against monkeypox virus M1R protein were developed. By screening fully humanized mice with antibodies, monoclonal antibodies M1R-12E10, M1R-12H5, M1R-12H6, M1R-24A7, and M1R-24H1 with strong specific binding ability, high affinity, and good in vitro neutralization were obtained. These antibodies were then expressed and purified in host cells using expression vectors.
These monoclonal antibodies exhibit good binding and neutralizing properties in vitro, providing protection against vaccinia virus and offering detection and treatment products for monkeypox virus, thus enabling the prevention and treatment of monkeypox virus infection.
Smart Images

Figure BDA0005314065620000051 
Figure BDA0005314065620000061 
Figure BDA0005314065620000071